Recent Updates — HLNCF

Haleon plc announced the pricing terms, expiration, and results of a cash tender offer for its outstanding $1,999,350,000 3.375% Fixed Rate Senior Notes due March 2027 issued by Haleon US Capital LLC. The transaction involves the repurchase of debt securities. Haleon plc is a consumer health company focused on everyday health products including brands such as Advil, Centrum, and Sensodyne.

Haleon plc announced the launch and pricing of a $2 billion three-tranche fixed-rate USD-denominated bond offering on August 13, 2026. The issuance consists of $600 million in senior notes maturing in 2029 with a 4.625% coupon, $600 million maturing in 2031 at 4.875%, and $800 million maturing in 2036 at 5.375%. Settlement is scheduled for August 21, 2026. Haleon intends to use the net proceeds, combined with cash on hand if necessary, to repurchase its outstanding $1,999,350,000 3.375% Fixed Rate Senior Notes due March 2027 through a concurrent tender offer announced on August 11, 2026. The offering is fully guaranteed by Haleon plc and managed by Barclays Capital Inc., BofA Securities, Inc., Deutsche Bank Securities Inc., Goldman Sachs & Co. LLC, and Mizuho Securities USA LLC. Haleon operates in the consumer health industry, manufacturing and selling over-the-counter medicines and personal care products.

Haleon plc announced a cash tender offer for all outstanding $1,999,350,000 of its 3.375% Fixed Rate Senior Notes due March 2027 through its subsidiary Haleon US Capital LLC. The transaction aims to proactively manage and optimize the company's debt portfolio in line with capital allocation priorities, alongside a planned new bond issuance. This activity is part of routine debt management rather than a significant restructuring or emergency financing event. Haleon plc operates as a global consumer health company focused on everyday health products.